Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 16/20 | 0.43 |
| ▸ | MAOB | P27338 | 8/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19251168 | 0.85 | POLB (0.47) | HRH3KDM4E | |
| SCHEMBL12459039 | 0.81 | MEN1 (0.40) | HRH3KDM4E | |
| SCHEMBL22752562 | 0.79 | NPC1 (0.37) | KDM4ENPC1RAB9A | |
| SCHEMBL18869669 | 0.79 | CASP1 (0.40) | HRH3MAOB | |
| SCHEMBL19252713 | 0.78 | CNR2 (0.36) | HRH3MAOB | |
| SCHEMBL14375993 | 0.78 | KDM4E (0.47) | HRH3MAOBKDM4E | |
| SCHEMBL9906408 | 0.77 | MEN1 (0.40) | HRH3KDM4E | |
| SCHEMBL9906447 | 0.76 | SMN1; SMN2 (0.42) | HRH3 | |
| SCHEMBL14376126 | 0.75 | TRPV1 (0.45) | HRH3MAOBKDM4E | |
| SCHEMBL24126961 | 0.74 | OGA (0.49) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10865216-B2 | Tricyclic Gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10865216-B2 | Tricyclic Gyrase inhibitors | TOP1, TOP2A, TOP2B | HRH3 4648/4885MAOB 409/4885KDM4E 2335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.